


Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in this application.

1. (Currently amended) ~~An acylhydroxamic acid derivative, selected from the group consisting of~~ A pharmaceutical composition comprising:

(a) ~~a compounds~~ compound of the formula:




or an acid addition salts thereof,

wherein

the carbon atom designated * constitutes a center of chirality,

R⁴ is hydrogen or -(C=O)-R¹²;

each of R¹ and R¹², independently of each other, is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridyl methyl, pyridyl, imidazolyl, imidazolyl methyl, or



wherein R* and R⁰, independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridylmethyl, pyridyl, imidazolyl or ~~imidazolylmethyl~~ imidazolylmethyl, and n = 0, 1, 2;

R⁵ is C=O, CH₂, ~~CH₂-CO-~~ -CH₂-CO-, or SO₂;

each of R⁶ and R⁷, independently of the other, is nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxy, carboxy, hydroxy, amino, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, cycloalkoxy of 3 to 8 carbon atoms, halo, bicycloalkyl of up to 18 carbon atoms, tricycloalkoxy of up to 18 carbon atoms, 1-

indanyloxy, ~~2-indanyloxy~~ 2-indanyloxy, C₄-C₈-cycloalkyldenemethyl, or C₃-C₁₀-alkyldenemethyl; and

each of R⁸, R⁹, R¹⁰, and R¹¹ independently of the others, is


- (i) hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, carbamoyl, acetoxo, carboxy, hydroxy, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, alkoxy of 1 to 10 carbon atoms, halo, or
- (ii) one of R⁸, R⁹, R¹⁰, and R¹¹ is acylamino comprising a lower alkyl, and the remaining of R⁸, R⁹, R¹⁰, and R¹¹ are hydrogen, or
- (iii) hydrogen if R⁸ and R⁹ taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (iv) hydrogen if R¹⁰ and R¹¹, taken together are benzo, quinoline, quinoxaline, benzimidazole, benzodioxole, 2-hydroxybenzimidazole, methylenedioxy, dialkoxy, or dialkyl, or
- (v) hydrogen if R⁹ and R¹⁰ taken together are benzo; and

(b) ~~The acid addition salts of said compounds which contain a nitrogen atom capable of being protonated~~ a pharmaceutically acceptable carrier.

Claims 2-4. Cancelled

5. (Currently amended) ~~An acylhydroxamic acid derivative~~ A pharmaceutical composition comprising:

(a) a compound of the formula ~~according to claim 1 wherein said compound has the formula:~~



or an acid addition salt thereof,

in which

the carbon atom designated * constitutes a center of chirality;

R⁴ is hydrogen or -(C=O)-R¹², where

each of R¹ and R¹², independently of each other, is alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridyl, pyridyl methyl, imidazolyl, imidazolymethyl, or CHR^{*}(CH₂)_nNR^{*}R⁰

wherein R^{*} and R⁰, independently of the other, are hydrogen, alkyl of 1 to 6 carbon atoms, phenyl, benzyl, pyridylmethyl, pyridyl, imidazolyl or imidazolymethyl, and n = 0, 1, 2;

R⁵ is C=O or CH₂;

each of R⁶ and R⁷, independently of the other is alkoxy of 1 to 8 carbon atoms, cycloalkoxy of 3 to 6 carbon atoms.; ~~C₄-C₆-cycloalkyldenemethyl~~ C₄-C₆-cycloalkyldenemethyl, ~~C₂-C₁₀-alkyldenemethyl~~ C₂-C₁₀-alkyldenemethyl, C₆-C₁₈-bicycloalkoxy, C₆-C₁₈-tricycloalkoxy, 1-indanyloxy, or 2-indanyloxy; ~~and~~

each of R⁸, R⁹, R¹⁰, and R¹¹, independently of the others, is hydrogen, nitro, cyano, trifluoromethyl, carbethoxy, carbomethoxy, carbopropoxy, acetyl, halo, carbamoyl, acetoxyl, carboxyl, hydroxyl, amino, alkylamino, dialkylamino, acylamino, alkyl of 1 to 10 carbon atoms, and alkoxy of 1 to 10 carbon atoms; ~~and~~

(b) a pharmaceutically acceptable carrier.

Claims 6-18. Cancelled

19. (Currently amended) The pharmaceutical composition ~~comprising a quantity of an acylhydroxamic acid derivative according to of claim 1, which derivative~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof, ~~suffieient upon administration in a single or multiple dose regimen to and wherein the composition is useful for reduce reducing or inhibit inhibiting levels of~~ TNF α or PDE 4 or a matrix metalloproteinases in a mammal ~~in combination with a carrier~~.

20. Cancelled.

21. (Currently amended) A method of inhibiting ~~the undesirable~~ levels of TNF α in a mammal which comprises administering thereto ~~an effective amount of an acylhydroxamic acid derivative~~ a pharmaceutical composition according to claim 1, ~~wherein said compound which derivative~~ is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

22. (Currently amended) A method of inhibiting ~~the undesirable~~ levels of matrix metalloproteinases in a mammal which comprises administering thereto ~~an effective amount of an acylhydroxamic acid derivative~~ a pharmaceutical composition according to claim 1, ~~wherein said compound which derivative~~ is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

23. (Currently amended) A method of treating an inflammatory or an autoimmune disease in a mammal ~~a disease selected from the group consisting of inflammatory disease and or autoimmune disease~~, which comprises administering thereto ~~an effective amount of a compound~~ pharmaceutical composition according to claim 1, ~~wherein said compound~~ is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

24. (Currently amended) A ~~The~~ method according to claim 23 wherein the disease is ~~at least one member selected from the group of~~ arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, aphthous ulcers, cachexia, graft versus host disease, asthma, chronic obstructive pulmonary disease COPD, psoriasis, atopic dermatitis,

~~Lupus~~lupus, adult respiratory distress syndrome, and or acquired immune deficiency syndrome.

25. (Currently amended) A method of treating cancer in a mammal which comprises administering thereto ~~an effective amount of a compound~~ pharmaceutical composition according to claim 1, ~~which~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

26. (Currently amended) A method of ~~treating~~ reducing angiogenesis ~~undesirable angiogenesis~~ in a mammal which comprises administering thereto ~~an effective amount of a compound~~ pharmaceutical composition according to claim 1, ~~which~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

27. (Currently amended) A method of inhibiting the levels of phosphodiesterases type IV ~~or PDE 4~~ in a mammal which comprises administering thereto ~~an effective amount of an acylhydroxamic acid derivative~~ a pharmaceutical composition according to claim 1, ~~which derivative~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

Claims 28-29. Cancelled.

30. The pharmaceutical composition ~~comprising a quantity of an acylhydroxamic acid derivative according to~~ of claim 5, ~~which derivative~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof, ~~sufficient upon administration in a single or multiple dose regimen to reduce or inhibit~~ wherein the composition is useful for reducing or inhibiting the levels of TNF α , PDE 4 or a matrix metalloproteinase in a mammal ~~in combination with a carrier~~.

31. Cancelled.

32. (Currently amended) A method of reducing or inhibiting the ~~undesirable~~ levels of TNF α in a mammal which comprises administering thereto ~~an effective amount of an acylhydroxamic acid derivative~~ a pharmaceutical composition according to claim 5, ~~which derivative~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

33. (Currently amended) A method of inhibiting ~~the undesirable~~ levels of matrix metalloproteinases in a mammal which comprises administering thereto ~~an effective amount of an acylhydroxamic acid derivative~~ a pharmaceutical composition according to claim 5, ~~which derivative~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

34. (Currently amended) A method of treating an inflammatory disease or an autoimmune disease in a mammal ~~a disease selected from the group consisting of inflammatory disease and or autoimmune disease~~, which comprises administering thereto ~~an effective amount of a compound~~ composition according to claim 5, ~~which~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

35. (Currently amended) A The method according to claim 34, wherein the disease is ~~at least one member selected from the group consisting of~~ arthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's disease, aphthous ulcers, cachexia, graft versus host disease, asthma, chronic obstructive pulmonary disease COPD, psoriasis, stopic dermatitis, ~~Lupus~~, adult respiratory distress syndrome, ~~and or~~ or acquired immune deficiency syndrome.

36. (Currently amended) A method of treating cancer in a mammal which comprises administering thereto ~~an effective amount of a compound~~ a pharmaceutical composition according to claim 5, ~~which~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

37. (Currently amended) A method of ~~treating~~ reducing angiogenesis ~~undesirable angiogenesis~~ in a mammal which comprises administering thereto ~~an effective amount of a compound~~ a pharmaceutical composition according to claim 5, ~~which~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

38. (Currently amended) A method of inhibiting ~~the undesirable~~ levels of phosphodiesterase type IV in a mammal which comprises administering thereto ~~an effective amount of an acylhydroxamic acid derivative~~ a pharmaceutical composition according to

claim 5, ~~which derivative~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

39. (Currently amended) A method of treating dermal diseases in a mammal which comprises administering thereto ~~an effective amount of an acylhydroxamic acid derivative~~ a pharmaceutical composition according to claim 5, ~~which derivative~~ wherein said compound is a substantially chirally pure (R)-isomer, a substantially chirally pure (S)-isomer, or a mixture thereof.

Claim 40. Cancelled.